presented the large, non-randomised, comparative, prospective study of clinical outcomes after RAPN or OPN at 9 high-volume European, North American, and Asian institutions [1]. The rationale behind this study was that although RAPN is commonly used, there had been little evidence conclusively indicating that one approach was better than the other.
The researchers prospectively identified patients (n=3,468) diagnosed with a cT1-2 cN0 cM0 renal mass who underwent RAPN (n=2,405) or OPN (n=1,063). Detailed preoperative data concerning the tumours was not documented in this study. Clinical outcomes were collected in a central database. For the purposes of this analysis, the authors examined perioperative complications, renal function, and cancer control. Regression analysis and propensity-score matching were used to account for all measurable potential confounders with special attention to key determinants of clinical outcomes including tumour complexity and surgical experience.
Outcomes favoured patients undergoing RAPN compared with OPN for the rate of intraoperative complications (5.7% vs 9.3%; OR 0.39; 95% CI 0.22-0.68; P<0.001) and overall complications (18% vs 33%; OR 0.29; 95% CI 0.12-0.60; P<0.001; see Table). Patients receiving RAPN also lost significantly less blood and had significantly shorter hospital stays. With a median follow-up of 32 months, oncologic outcomes and longer-term survival outcomes were similar between groups, including positive surgical margins (4.3% vs 5.1%), local recurrence (1.6% vs 2.1%), systemic progression (1.8% vs 4.5%), and cancer-specific mortality (0.8% vs 2.4%). However, RAPN was associated with slightly longer ischaemia times (16 vs 15 minutes) and lower post-operative kidney function when compared with OPN. However, the renal function in both groups was similar within 1 year, suggesting that this is a transient phenomenon.
Table: Clinical outcomes of patients treated with OPN versus RAPN [1]
OPN, open partial nephrectomy; RAPN, robot-assisted partial nephrectomy; eGFR, estimated glomerular filtration rate
After stratification according to complication severity or type, RAPN was associated with a lower rate of complications compared with OPN, including Clavien-Dindo ≥2 (12% vs 20%), Clavien-Dindo ≥3 (4.0% vs 6.1%), haemorrhagic (6.4% vs 9.0%), and urinary leakage-related (0.8% vs 4.6%) complications.
In conclusion, overall morbidity is lower after RAPN relative to OPN. Early renal function preservation is inferior after RAPN versus OPN, but no differences were observed at long-term follow-up. Oncologic outcomes are similar after either treatment modality. The trend towards worse progression rates following OPN raises the question of whether there was an underlying negative selection in this cohort due to worse pre-operative tumour characteristics; baseline tumour data were not collected in this study.
- Larcher A, et al. EAU20 Virtual Congress, 17-26 July 2020, Abstract 30.
Posted on
Previous Article
« Pressure and temperature: do high-power lasers pose a threat? Next Article
Debate: upfront cytoreductive nephrectomy or not? »
« Pressure and temperature: do high-power lasers pose a threat? Next Article
Debate: upfront cytoreductive nephrectomy or not? »
Table of Contents: EAU 2020
Featured articles
Surgical Techniques and Safety
The new adjustable artificial sphincter victo: Surgical technique and results after a follow-up of more than one year
New urosepsis data from the SERPENS study
Stones
Intra-operative cone-beam computed tomography for detecting residual stones in percutaneous nephrolithotomy
Pressure and temperature: do high-power lasers pose a threat?
Radiation stewardship for patient and endourologist
New lithotripter data: improved stone clearance
Renal Cancer
Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses
Imaging guided surgery with augmented reality for robotic partial nephrectomy
KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib
Debate: upfront cytoreductive nephrectomy or not?
Robotic-assisted partial nephrectomy: lower morbidity
Bladder Cancer
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Prostate Cancer & Imaging
Transperineal laser ablation of prostate
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
BPH & LUTS
Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release
LUTS 2-year outcomes: aquablation versus TURP
HoLEP versus PVP in prospective randomised trial
Testis Cancer & Andrology
Peyronie’s disease: surgical options
Infertility and testis cancer risk: causal or association?
32% more men complain of reduced sex drive in 2019 versus 2009
Related Articles
October 21, 2020
Rates of bone density testing in men initiating ADT low but rising
August 31, 2021
Best of EAU: Updates on imaging and treatment of prostate cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com